Introduction
Premature ovarian failure (POF) is classically defined as 4 to 6 months of amenorrhea in women under the age of 40 years, who have elevated serum follicle stimulating hormone (FSH) levels (hypergonadotropic hypogonadism, usually over 40 IU/L) and low estradiol level (less than 50 pg/mL). 1 4, 5 POF is characterized by loss of follicles, ovarian function, and estrogen production, and finally resulting in infertility. 6, 7 Its incidence is estimated to be as high as 1 in 100 by the age of 40, and 1 in 1,000 by the age of 30. Potential etiologies for POI are genetic, autoimmune, metabolic, infectious, and iatrogenic (ovarian surgery, radiotherapy, or chemotherapy) factors. 3, 8 Importantly, early ovarian failure is a cause of refractory infertility and management for POI should reflect a comprehensive approach. To date, many treatment methods have been applied and they include hormone replacement therapy, 9 in vitro fertilization methods, 10 and cell therapy using stem cells. 11~14 However, effective treatments and drugs for POF treatment are very limited. Therefore, new strategies for improving treatment are absolutely required. 15, 16 In this respect, many studies have used POF animal models to identify molecular mechanisms of POF and to develop the therapeutic agents. 17, 18 Currently, POF animal models are being made using various anticancer drugs. Cyclophosphamide (CTX), busulfan (Bu), and cisplatin are representative anticancer drugs. However, the POF induction effect of these anticancer drugs varies widely depending on the treatment period and concentration. Especially, when POF is induced by an anticancer drug and then the anticancer drug is stopped, POF can be recovered naturally as time goes by.
Most studies overlook this point. Therefore, this study is aimed to suggest the most effective POF mouse model using CTX, Bu, and cisplatin considering treatment duration of anticancer drugs and natural recovery time.
Materials and Methods
Experimental animals
All experimental mice were purchased from Hanasangsa (Busan, Korea) and housed in a temperature-and humiditycontrolled animal facility under a 12-hours light-dark cycles with food and water available ad libitum. All experiments were performed in accordance with 'the Guide for the Care 
Results

Changes in body weight, ovarian and uterine weight after CTX/Bu treatment
Whether the CTX/Bu treatment affects body weight, ovarian weight and uterine weight was examined according to the treatment period. As the treatment period increased, the weight of ovaries and uterus as well as body weight decreased significantly. In particular, after 2 weeks of treatment, the weight of ovaries and uterus decreased sharply (Table 1) . (Table 2 ). This result means that the CTX/ Bu treatment reduced not only body weight and ovarian and uterine weight, but also ovarian function.
Changes in ovarian function
3. Natural recovery of ovarian failure after stopping CTX/Bu treatment In order to investigate how long the ovarian function of However, when CTX/Bu was injected for 2 weeks, ovarian function was not recovered at all after the recovery period of 2 weeks (Table 3 ). This result means that ovarian function is not naturally recovered for at least 2 weeks when POF is induced with CTX/Bu for 2 weeks.
4. Changes in body weight, ovaries and uterine weight after cisplatin treatment In other experiment, we examined the effect of cisplatin treatment for POF induction on body weight, ovarian and uterine weight according to the cisplatin treatment period.
As the treatment period increased, the weight of ovaries and uterus as well as body weight decreased. In particular, from 10 days of cisplatin injection, the weight of ovaries and uterus decreased significantly (Table 4) . (Table 5 ). This result means that oocyte quality began to deteriorate from 5 days of cisplatin treatment, and ovarian function was sufficiently inhibited by treatment for 10 days or more. 
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6. Natural recovery of POI after stopping cisplatin treatment Finally, we examined how long the ovarian function of POF-induced mice was recovered naturally after the last injection of cisplatin. When the mice were injected with cisplatin for 10 days and then were left untreated for 1 week, the average number of zygotes retrieved was 13.6, which was nearly same as the control group (13.0), but the embryo development rate to blastocyst was 0%. When cisplatin was injected for 10 days and then left untreated for 1 week, the average number of zygotes retrieved and embryo development rate were 3.25 and 0%, which was significantly reduced compared to the control group (Table 6 ). Therefore, this result means that when inducing a POF model with cisplatin, it is most preferable to inject for 10 to 14 days.
Discussion
Ovarian aging is the main cause of age-related decline in fertility in women, and this is one of the most difficult causes to resolve in the treatment of infertility. For this reason, our research team was working on the development of a substance that could overcome or rescue ovarian aging and have tried to establish the mouse POF as a model for evaluating the efficacy of such substance. Among many anticancer drugs, CTX, Bu, and cisplatin have been widely used to induce POF models. However, the concentration and duration of treatment were very different for each researcher.
Jiang et al. 19 reported that when CTX (120 mg/kg) and Bu (12 mg/kg) was injected daily to female mice at 2 months of age, there was no difference in body weight, the ovary size was slightly smaller, and the number of follicles was significantly reduced at 30 days in CTX/Bu-treated mice compared to the control group. In a study of Zhang et al. 20 comparing the induction effects of POF by different anticancer drugs, they showed that when CTX and Bu were treated alone for 30 days, there was no difference in body weight, related serum hormonal level, and pathological changes in ovary and uterus. Previously, it has reported that CTX and Bu have relatively low toxicity compared to other anticancer drugs, 21, 22 but they induced the sufficient damage to the In this respect, the present study clearly shows that it is most effective to use 14 days for CTX/Bu and 10 to 14 days for cisplatin to establish the POF model in mice. These treatment periods not only reliably induced ovarian failure by inhibiting ovarian function, but were not recovered naturally for at least 2 weeks, making it very useful for investigating the improvement effect of ovarian failure for the 2 weeks.
Whether ovarian failure is induced well is verified by several factors, which include body weight, locomotor activity, ovarian and uterine weight, folliculogenesis and follicle counting on ovarian histology, and serum estradiol and FSH concentration, etc. In the present study, body weight, ovarian and uterine weight, and ovarian function were examined to assess whether POF was induced. Ovarian function was defined by the number of zygotes retrieved after superovulation, and followed by mating and developmental competency.
One interesting finding is that changes in body weight can be a useful indicator of the induction of POF. In the present study, although anticancer drugs were administered for the same period, if the body weight did not decrease, ovarian function as well as ovarian and uterine size were normal. In contrast, if body weight was greatly reduced, ovarian and uterine size became very small and hard, and ovarian function was also severely inhibited. In addition, after the last injection of anticancer drugs, mice with rapidly increasing body weight were also recovering in size of the ovaries and uterus, and the ovarian function was also restored naturally. These results indicate that body weight change can be a primary effective indicator for POF induction.
In the induction of POF model, most studies have focused how anticancer drugs inhibit ovarian function and follicular development. However, in addition to this, it is also very important to identify the period during which the inhibited ovarian function is naturally recovered. If we are performing a study to develop a new substance to treat POF and the period of treatment of this substance is 2 weeks, it should be confirmed that induced ovarian failure does not naturally recover within a period of at least 2 weeks after the last administration of anticancer drugs. This is because it is possible to distinguish whether the recovery of ovarian failure is due to a drug or a natural recovery. However, reports on the natural recovery period of ovarian failure are very limited.
Sun et al. 11 reported that the POF mice did not recover to the normal level within 1 month when CTX (50 mg/kg) was intraperitoneally administered for 15 consecutive days. Liu et al. 17 showed no change in ovarian weight after 14 days of CTX (70 mg/mg) injection. Wang et al. 14 showed that in the POF mice induced by cisplatin (2 mg/kg) treatment for 7 consecutive days, ovarian weight and follicle counts were significantly decreased at 21 days, indicating that ovarian failure by cisplatin was not recovered naturally until 21 days. These results are somewhat different from results of our present study, which showed that ovarian failure was not restored naturally until 2 weeks after CTX/Bu injection for 2 weeks, and one week after cisplatin injection for more than 10 days. The difference in these results may be due to differences in the concentrations of anticancer drugs and the species of mice used in the experiment.
In conclusion, these results suggest that CTX (120 mg/ kg)/Bu (12 mg/kg) should be treated for at least over 2 weeks and cisplatin (2 mg/kg) for at least over 10 days to establish the most effective POI mouse model, assuming no spontaneous recovery for at least 2 weeks unless these anticancer drugs cause rapid body weight loss and death of the mice. In the future, this study may contribute to the effective establishment of the POF mouse model for the development of therapeutic drugs and the study of mechanism of POF.
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